COVID-19: Zydus Cadila gets DCGI nod for phase-III clinical trials

Ahmedabad based Zydus Cadila Pharmaceuticals has announced that the company has received an approval from the Drugs Controller General of India -DCGI to begin the phase-III clinical trials with its biological therapy Pegylated Interferon alpha-2b (PegiHep) in Covid-19 patients.

PegiHep is an approved drug and is being re-purposed for the treatment of Covid-19. According to sources, the trials will be conducted on 250 patients across 25 centres in India during this month. The Ahmedabad-based healthcare major had completed the phase-2 clinical trial last month. The second phase trials indicated that this biological drug had a beneficial impact on the patient suffering from moderate Covid-19 disease by reducing their viral load. According to sources, a single dose therapy will improve compliance and make it highly affordable for patients.

Apart from this, Zydus has also completed the phase-II human clinical trials of its vaccine candidate- ZyCov-D for Covid-19 and its results are currently analysed.


The Dispatch is present across a number of social media platforms. Subscribe to our YouTube channel for exciting videos; join us on Facebook, Intagram and Twitter for quick updates and discussions. We are also available on the Telegram. Follow us on Pinterest for thousands of pictures and graphics. We care to respond to text messages on WhatsApp at 8082480136 [No calls accepted]. To contribute an article or pitch a story idea, write to us at [email protected] |Click to know more about The Dispatch, our standards and policies